title: Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.
authors.forename: Matthias
authors.initials: M
authors.lastname: Jürgens
authors.forename: Stephan
authors.initials: S
authors.lastname: Brand
authors.forename: Levent
authors.initials: L
authors.lastname: Filik
authors.forename: Christoph
authors.initials: C
authors.lastname: Hübener
authors.forename: Uwe
authors.initials: U
authors.lastname: Hasbargen
authors.forename: Florian
authors.initials: F
authors.lastname: Beigel
authors.forename: Cornelia
authors.initials: C
authors.lastname: Tillack
authors.forename: Burkhard
authors.initials: B
authors.lastname: Göke
authors.forename: Thomas
authors.initials: T
authors.lastname: Ochsenkühn
authors.forename: Julia
authors.initials: J
authors.lastname: Seiderer
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab